Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Plos One|April 26, 2018
Bacillus megaterium strains derived from water and soil exhibit differential responses to the herbicide mesotrioneTatiane Dobrzanski, Fernanda Gravina, Bruna Steckling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2016
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessmentE Calura, L Paracchini, R Fruscio, et al.
Oncogene|November 12, 2013
Mode of action of trabectedin in myxoid liposarcomasS Di Giandomenico, R Frapolli, E Bello, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|September 1, 2018
Pharmacokinetics and cytotoxic study of euphol from Euphorbia umbellata (Bruyns) Pax latexLuiza S Cruz, Thais L de Oliveira, Carla C Kanunfre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective studyL Beltrame, M Di Marino, R Fruscio, et al.
ESMO Open|February 26, 2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trialL Paracchini, A Velle, P Di Gennaro, et al.
ESMO Open|January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialB Pellegrino, E D Capoluongo, M Bagnoli, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Pageof 4